Morgan Stanley
RAPP

Morgan Stanley’s Rapport Therapeutics RAPP Stock Holding History

Morgan Stanley’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4M Buy
297,612
+131,658
+79% +$4.84M ﹤0.01% 3525
2026
Q1 		$5.19M Sell
165,954
-44,377
-21% -$1.25M ﹤0.01% 4105
2025
Q4 		$6.38M Sell
210,331
-64,237
-23% -$1.78M ﹤0.01% 3996
2025
Q3 		$8.15M Buy
274,568
+205,105
+295% +$3.66M ﹤0.01% 3720
2025
Q2 		$790K Sell
69,463
-7,141
-9% -$75.8K ﹤0.01% 5229
2025
Q1 		$768K Buy
76,604
+53,968
+238% +$701K ﹤0.01% 5124
2024
Q4 		$402K Sell
22,636
-1,592
-7% -$35.3K ﹤0.01% 5510
2024
Q3 		$496K Buy
+24,228
New +$521K ﹤0.01% 5412

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Morgan Stanley's RAPP Position: Q2 2026 in Review

Morgan Stanley increased its Rapport Therapeutics (RAPP) stake by 79% in Q2 2026, buying an estimated $4.84M and bringing the position to 297,612 shares worth $12.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3525.

Morgan Stanley first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Morgan Stanley held 297,612 shares of Rapport Therapeutics worth $12.4M as of Q2 2026.
  • Morgan Stanley bought 131,658 Rapport Therapeutics shares in Q2 2026, an estimated $4.84M.
  • Rapport Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3525 holding.
  • Morgan Stanley first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.